This is a recording from the Cardiomyopathy UK 2022 Conference.
Our conference events bring together leading cardiomyopathy clinicians to present and respond to audience questions.
In this video, Mr Alex Shipolini discusses the invasive management options for Hypertrophic Obstructive Cardiomyopathy (HoCM).
Notice – This video contains graphic images from 00:42:30 – 00:46:07 depicting a septal myectomy open heart surgery.
Chapters:
00:00:59 – Scope of this presentation
00:01:48 – What is Hypertrophic Obstructive Cardiomyopathy (HoCM)?
00:04:05 – Left Ventricular Outflow Tract Obstruction (LVOTO)
00:10:02 – How do we make a diagnosis?
00:14:31 – Echo gradient assessment
00:16:08 – HCM symptoms
00:17:25 – How is HCM managed?
00:18:37 – Prognostic interventions
00:20:05 – Sudden Cardiac Death (SCD) risk assessment
00:23:08 – Stroke risk
00:25:51 – Heart failure
00:27:20 – Symptom management
00:30:09 – Mavacamten
00:31:09 – Invasive treatment options
00:37:21 – Septal myectomy for HoCM
00:42:30 – [Graphic images warning] – Septal myectomy open heart surgery
00:46:32 – Cardiomyopathy Team
00:47:42 – Alcohol septal ablation vs.. septal myectomy
00:50:38 - Conclusion
Audience Questions
00:51:53 – Could mavacamten mark the end of surgical interventions for HoCM?
00:54:13 – Will mavacamten be cheaper than the cost of surgery to the NHS?
00:55:33 – Can people with an ICD get a myectomy?
00:55:47 – Is it possible to have a myectomy after having an ablation?
00:57:17 – Is there a risk of infection to the heart from surgery?
00:58:16 – Why do you operate on more men than women?
00:58:50 – Can you treat all types of hypertrophic cardiomyopathy with a myectomy?
Access free information, find out about support groups and speak with cardiomyopathy Specialist Nurses at www.cardiomyopathy.org
